Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Pennant Investors, LP

Q1 2024 · 13F-HR

Pennant Investors, LPholdings as filed

Filed 2024-05-15 · accession 0000919574-24-003124

$403.7M
Reported value
45
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
023135106AMZNAMAZON COM INC$53.4M13.2%296,000CommonSOLE
893641100TDGTRANSDIGM GROUP INC$51.7M12.8%42,000CommonSOLE
594918104MSFTMICROSOFT CORP$47.1M11.7%112,000CommonSOLE
595112103MUMICRON TECHNOLOGY INC$36.1M8.94%306,000CommonSOLE
03674X106ARANTERO RESOURCES CORP$32.9M8.14%1,133,000CommonSOLE
278768106SATSECHOSTAR CORP$30.7M7.60%2,153,209CommonSOLE
02079K305GOOGLALPHABET INC$30.0M7.44%199,000CommonSOLE
037833100AAPLAPPLE INC$27.4M6.80%160,000PUTSOLE
194014502ENOVENOVIS CORPORATION$25.0M6.19%400,000CommonSOLE
88337F105ODP1THE ODP CORP$21.2M5.26%400,000CommonSOLE
L7579L106PERIMETER SOLUTIONS SA$17.1M4.23%2,300,000CommonSOLE
03674X106ARANTERO RESOURCES CORP$14.5M3.59%500,000CALLSOLE
31572Q808FGENEURFIBROGEN INC$1.8M0.45%768,400CommonSOLE
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$1.7M0.42%170,900CommonSOLE
02155H200ALTALTIMMUNE INC$1.1M0.28%109,800CommonSOLE
31189P102FATEFATE THERAPEUTICS INC$1.1M0.27%146,100CommonSOLE
67080M103NRIXNURIX THERAPEUTICS INC$834,9600.21%56,800CommonSOLE
556099109MGNXMACROGENICS INC$644,7360.16%43,800CommonSOLE
4495851081K0IGM BIOSCIENCES INC$626,2850.16%64,900CommonSOLE
29251M106ENTAENANTA PHARMACEUTICALS INC$612,8460.15%35,100CommonSOLE
019770106ALLOALLOGENE THERAPEUTICS INC$573,9480.14%128,400CommonSOLE
282559103ETNBGBP89BIO INC$517,9800.13%44,500CommonSOLE
98943L107ZNTLZENTALIS PHARMACEUTICALS INC$510,6240.13%32,400CommonSOLE
03969F109RCUSARCUS BIOSCIENCES INC$447,4560.11%23,700CommonSOLE
03969T109ARCTARCTURUS THERAPEUTICS HLDGS$442,3870.11%13,100CommonSOLE
00847X104AGIOAGIOS PHARMACEUTICALS INC$441,5240.11%15,100CommonSOLE
761299AB2TVTX 2.5 09/15/25TRAVERE THERAPEUTICS INC$430,2180.11%55,800CommonSOLE
37427G101GETRGETAROUND INC$413,8830.10%1,348,153CommonSOLE
98985Y108ZYMEZYMEWORKS INC$407,1240.10%38,700CommonSOLE
19249H103CHRSCOHERUS BIOSCIENCES INC$401,7590.10%168,100CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$394,0200.10%199,000CommonSOLE
75943R102RLAYRELAY THERAPEUTICS INC$351,9200.09%42,400CommonSOLE
29479A108ERASERASCA INC$342,3720.08%166,200CommonSOLE
78667J108SG7SAGE THERAPEUTICS INC$327,9500.08%17,500CommonSOLE
670002401NVAXNOVAVAX INC$288,2340.07%60,300CommonSOLE
00847G705AGENEURAGENUS INC$272,3680.07%469,600CommonSOLE
N90064101QUREUNIQURE NV$252,2000.06%48,500CommonSOLE
76029N106REPLREPLIMUNE GROUP INC$249,1850.06%30,500CommonSOLE
09075P105BTAIEURBIOXCEL THERAPEUTICS INC$236,5980.06%83,900CommonSOLE
01671P100ALLKGUSDALLAKOS INC$234,4860.06%186,100CommonSOLE
81750R102MCRB1EURSERES THERAPEUTICS INC$226,2690.06%292,300CommonSOLE
019818103ALLOVIR INC$162,8320.04%215,700CommonSOLE
00951K104AIRSPAN NETWORKS HOLDINGS IN$118,3640.03%1,047,473CommonSOLE
09609G100BLUEBIRD BIO INC$111,8720.03%87,400CommonSOLE
G4124C117GRABWGRAB HOLDINGS LIMITED$16,2080.00%80,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.